Last reviewed · How we verify
Beclometasone/Formoterol
Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects.
Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Beclometasone/Formoterol |
|---|---|
| Also known as | Foster® or CHF 1535 pMDI 100/6 mcg, Fostair 100/6 |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination |
| Target | Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Beclometasone binds to glucocorticoid receptors in the lungs, suppressing inflammatory cell recruitment and cytokine production. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation. The combination provides both rapid symptom relief and sustained control of airway inflammation in obstructive airway diseases.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness/anxiety
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beclometasone/Formoterol CI brief — competitive landscape report
- Beclometasone/Formoterol updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI